TY - JOUR
T1 - Considerations on antimicrobial prophylaxis in patients with lymphoproliferative diseases
T2 - A SEIFEM group position paper
AU - SEIFEM (Sorveglianza Epidemiologica delle InFezioni nelle EMopatie)
AU - Busca, Alessandro
AU - Cattaneo, Chiara
AU - De Carolis, Elena
AU - Nadali, Gianpaolo
AU - Offidani, Massimo
AU - Picardi, Marco
AU - Candoni, Anna
AU - Ceresoli, Eleonora
AU - Criscuolo, Marianna
AU - Delia, Mario
AU - Della Pepa, Roberta
AU - Del Principe, Ilaria
AU - Fanci, Roma Rosa
AU - Farina, Francesca
AU - Fracchiolla, Nicola
AU - Giordano, Claudia
AU - Malagola, Michele
AU - Marchesi, Francesco
AU - Piedimonte, Monica
AU - Prezioso, Lucia
AU - Quinto, Angela Maria
AU - Spolzino, Angelica
AU - Tisi, Maria Chiara
AU - Trastulli, Fabio
AU - Trecarichi, Enrico Maria
AU - Zappasodi, Patrizia
AU - Tumbarello, Mario
AU - Pagano, Livio
N1 - Copyright © 2020. Published by Elsevier B.V.
PY - 2021/2
Y1 - 2021/2
N2 - The therapeutic armamentarium for the treatment of patients with lymphoproliferative diseases has grown considerably over the most recent years, including a large use of new immunotherapeutic agents. As a consequence, the epidemiology of infectious complications in this group of patients is poorly documented, and even more importantly, the potential benefit of antimicrobial prophylaxis remains a matter of debate when considering the harmful effect from the emergence of multidrug resistant pathogens. The present position paper is addressed to all hematologists treating patients affected by lymphoproliferative malignancies with the aim to provide clinicians with a useful tool for the prevention of bacterial, fungal and viral infections.
AB - The therapeutic armamentarium for the treatment of patients with lymphoproliferative diseases has grown considerably over the most recent years, including a large use of new immunotherapeutic agents. As a consequence, the epidemiology of infectious complications in this group of patients is poorly documented, and even more importantly, the potential benefit of antimicrobial prophylaxis remains a matter of debate when considering the harmful effect from the emergence of multidrug resistant pathogens. The present position paper is addressed to all hematologists treating patients affected by lymphoproliferative malignancies with the aim to provide clinicians with a useful tool for the prevention of bacterial, fungal and viral infections.
KW - Anti-Bacterial Agents/therapeutic use
KW - Anti-Infective Agents/therapeutic use
KW - Humans
KW - Lymphoproliferative Disorders/drug therapy
U2 - 10.1016/j.critrevonc.2020.103203
DO - 10.1016/j.critrevonc.2020.103203
M3 - Review article
C2 - 33388453
VL - 158
SP - 103203
JO - Critical Reviews in Oncology/Hematology
JF - Critical Reviews in Oncology/Hematology
SN - 1040-8428
ER -